Dr. Reddy's Laboratories launches Chlordiazepoxide Hydrochloride and Clidinium Bromide Capsules, USP in the U.S. Market

Dr. Reddy's Laboratories Ltd. (BSE: 500124, NSE: DRREDDY, NYSE: RDY, NSEIFSC: DRREDDY, along with its subsidiaries together referred to as "Dr. Reddy's") today announced the launch of Chlordiazepoxide Hydrochloride and Clidinium Bromide Capsules USP, 5 mg/2.5 mg, a therapeutic equivalent generic version of Librax® (chlordiazepoxide hydrochloride and clidinium bromide) approved by the U.S. Food and Drug Administration (USFDA).

The Librax® brand and generic market had U.S. sales of approximately $105.9 million MAT for the most recent twelve months ending in July 2021 according to IQVIA Health*.

Dr. Reddy's Chlordiazepoxide Hydrochloride and Clidinium Bromide Capsules, USP are available in one strength of 5 mg/2.5 mg capsules in bottle count sizes of 100.

Shares of Dr. Reddy's Laboratories Ltd., was last trading in BSE at Rs. 4678.35 as compared to the previous close of Rs. 4601.25. The total number of shares traded during the day was 54163 in over 5504 trades.

The stock hit an intraday high of Rs. 4699.15 and intraday low of 4576.75. The net turnover during the day was Rs. 252684766.

Source : Equity Bulls

Keywords